Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis
NCT ID: NCT02824419
Last Updated: 2016-07-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
10 participants
INTERVENTIONAL
2016-05-31
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SARCOLOWDOSE : Ultra-low Dose CT Scan and MRI in Thoracic Sarcoidosis
NCT03140644
Difference Strain Ratio Ultrasound Elastography Between Benign and Malignant Peripheral Lung Lesions
NCT05752227
Peripheral Airway Biopsy in Sarcoidosis
NCT05759221
Lung CT Scan Analysis of SARS-CoV2 Induced Lung Injury
NCT04395482
Sarcoidosis Immunotsuppressive Therapy and Lymphoma Development
NCT07343401
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The patients with active sarcoidotic lesions in lungs will be recruited. First, the patient undergoes PET-FDG scan and then the patient undergoes the PET scan either with C11-methionine or 68Ga-DOTANOC. The results with the latter tracers will be compared to the imaging results with FDG.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
C11-methionine
To compare FDG and C11-methionine in the detection of sarcoidotic lesions.
Methionine
Subject undergoes imaging studies with FDG and with methionine.
68Ga-Dotanoc
To compare FDG and 68Ga-DOTANOC in the detection of sarcoidotic lesions.
DOTANOC
Subject undergoes imaging studies with FDG and with DOTANOC.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Methionine
Subject undergoes imaging studies with FDG and with methionine.
DOTANOC
Subject undergoes imaging studies with FDG and with DOTANOC.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* any significant other inflammatory or infectious disease affecting lungs
* pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Turku University Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juhani Knuuti, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Turku PET Centre, Turku University Hospital, Turku, Finland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Turku University Hospital
Turku, Southwest Finland, Finland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Juhani Knuuti, MD, PhD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
T16/2015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.